Eris Lifesciences Q3 Review - New Launches, Better MR Output To Lead Growth In FY22: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Eris Lifesciences Ltd.’s Q3 FY21 earnings were in-line with our estimates led by growth in top brands and pick up in marketing acitivies.
The company continues to outperform its peers and Indian pharma market led by strong growth in chronic products that contribute 75-85% revenues.
Management guided for -
1. New launches and better medical representative productivity to lead growth in FY22E
2. launch derma products with addition of new MRs within next two quarters and
3. will continue to outperform in covered markets and IPM.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.